Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...